EGFR-TKI类药物治疗晚期非小细胞肺癌的研究进展

Research Advances of EGFR-TKI Drugs in Advanced NSCLC

关键词:  非小细胞肺癌  表皮生长因子  酪氨酸激酶抑制剂

Key words:  non-small cell lung cancer  epidermal growth factor  tyrosine kinase inhibitor

摘要:

表皮生长因子受体酪氨酸激酶抑制剂（epithelial growth factor receptor tyrosine kinase inhibitors，EGFR-TKI）引领EGFR突变的晚期非小细胞肺癌精准治疗十多年，EGFR-TKI对EGFR常见突变的晚期非小细胞肺癌的疗效已得到明确的证实。然而对于EGFR罕见突变，EGFR-TKI的疗效在临床上存在众多争议。本文列举了目前已经进入临床阶段的EGFR-TKI类药物在EGFR突变阳性晚期非小细胞肺癌中的中位无进展及总生存期并进行比较，增加了EGFR罕见突变对EGFR-TKI疗效的相关研究，以期为临床EGFR-TKI的合理使用提供参考。

Abstract:

Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) has continued to lend to the precise treatment of EGFR mutations in advanced non-small cell lung cancer for more than ten years, which the efficacy of EGFR-TKI for patients with common EGFR mutations in advanced NSCLC has been demonstrated clearly. However, for uncommon EGFR mutations, the efficacy of EGFR-TKI is still exist many dispates. This article lists the median progression-free and overall survival of the drugs of EGFR-TKI that have entered the clinical stage in EGFR mutation-positive advanced NSCLC currently making comparisons, and add correlation studies on the efficacy of EGFR-TKI for those patients with uncommon EGFR mutation. It is hoped to provide reference for rational application of EGFR-TKI in clinical.